NCT02717624Active, not recruitingPhase 1
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Jul 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- First submitted
- 1 Jul 2024
- Start date
- 5 Sept 2016
- Lead sponsor
- Acerta Pharma B.V.
- Diseases
- Mantle cell lymphoma
- EU CT number
- 2023-509353-31-00
- EudraCT number
- 2015-004487-11
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 6
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pratia S.A. Coordinator of this site? Confirm its status | Cracow | Poland | Active, not recruiting |
| Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi Coordinator of this site? Confirm its status | Lodz | Poland | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.